Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics Chief Executive Officer Abraham Ceesay, who is also a director, reported planned sales of company stock. On January 20, 2026, he sold 5,833 shares of common stock directly at a weighted average price of $26.1158, leaving him with 562,080 directly held shares.
On the same date, 5,083 shares of Rapport common stock were sold at a weighted average price of $26.114 by The Dorothy Ceesay Irrevocable Trust, which now holds 25,812 shares, and a separate Ceesay Family Irrevocable Trust holds 81,729 shares. All reported sales were made under Rule 10b5-1 trading plans adopted on December 12, 2024. The trusts are associated with Ceesay, but he disclaims beneficial ownership of their shares except to the extent of any pecuniary interest.
Rapport Therapeutics Inc. disclosed that BlackRock, Inc. has become a significant institutional holder of its common stock. BlackRock reports beneficial ownership of 2,397,549 shares of Rapport common stock, representing 5.03% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 2,355,378 shares and sole dispositive power over 2,397,549 shares, with no shared voting or dispositive authority. The filing explains that these holdings are attributed to specific BlackRock business units and that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Rapport’s outstanding shares. BlackRock certifies that the position was acquired in the ordinary course of business and not for the purpose of changing or influencing control of Rapport.
Rapport Therapeutics Chief Scientific Officer David Bredt reported selling common stock in the company. On January 15, 2026, he sold 8,300 shares of common stock at a weighted average price of $26.8255 and an additional 200 shares at $27.40. The weighted average sale was executed in multiple trades at prices ranging from $26.33 to $27.30. After these sales, Bredt beneficially owned 395,575 shares of common stock directly. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024, which is designed to allow insiders to sell shares according to a preset schedule.
David S. Bredt filed a notice of proposed sale under Rule 144 to sell 17,000 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. The filing lists an aggregate market value of $466,140.00 for these shares and notes that 47,661,138 shares of the issuer’s common stock are outstanding.
The shares to be sold were acquired as founder shares on 03/09/2023, with 17,000 securities acquired and paid for on the same date. Over the past three months, related sales of common stock by David S. Bredt include 6,567 shares sold on 12/31/2025 for $197,337.69, 8,500 shares sold on 12/15/2025 for $255,130.05, and 8,500 shares sold on 11/17/2025 for $214,090.35, with two of these transactions identified as Rule 10b5-1 sales.
Rapport Therapeutics, Inc. filed a prospectus supplement to its effective shelf registration statement to register the offer and sale of up to $110,000,000 of common stock through an at-the-market offering program. The shares may be sold from time to time through or to Leerink Partners LLC and Cantor Fitzgerald & Co., acting as sales agents under an existing Sales Agreement dated July 1, 2025. As of the date of this report, no sales of common stock have been made under the Sales Agreement. The company also filed the related legal opinion of Goodwin Procter LLP as an exhibit.
Rapport Therapeutics, Inc. is launching an at‑the‑market offering of up to $110,000,000 of its common stock under an existing shelf registration. The company has a sales agreement with Leerink Partners and Cantor Fitzgerald, which will act as sales agents and may sell shares from time to time on The Nasdaq Global Market under the symbol “RAPP.” The agents will receive a commission of up to 3.0% of the gross proceeds and will be deemed underwriters for regulatory purposes.
Rapport plans to use any net proceeds, together with existing cash and investments, primarily to fund research and clinical development of its precision neurology and psychiatry pipeline, including lead candidate RAP‑219, and to support broader R&D, working capital, capital expenditures and other general corporate purposes. As of September 30, 2025, 47,650,216 shares of common stock were outstanding, and the company warns investors about potential dilution, share price volatility, and the risks highlighted in its incorporated risk factors. Rapport is an emerging growth and smaller reporting company and uses reduced disclosure and extended timelines for new accounting standards.
Rapport Therapeutics, Inc. filed a current report describing new investor communications. On January 7, 2026, the company issued a press release titled “Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline,” which is furnished as an exhibit.
On the same date, Rapport updated its corporate presentation for use with investors, analysts and others, and made it available on the Investors section of its website. The updated presentation is also attached as an exhibit to this report.
Rapport Therapeutics, Inc. reported insider share sales by its chief executive officer and director on December 17, 2025, executed under Rule 10b5-1 trading plans adopted on December 12, 2024. The reporting person sold several blocks of common stock, including 2,441 shares at a weighted average price of $28.8378, 2,792 shares at $30.0365, and 600 shares at $31.036, with additional sales through an irrevocable trust at weighted average prices between roughly $28.84 and $31.04 per share, as disclosed in the footnotes.
Following these transactions, the reporting person beneficially owns 567,913 shares of common stock directly, and indirectly holds 30,895 shares through The Dorothy Ceesay Irrevocable Trust and 81,729 shares through The Ceesay Family Irrevocable Trust. The filing states that beneficial ownership of the trust-held shares is disclaimed except to the extent of any pecuniary interest.
Rapport Therapeutics, Inc. reported that its Chief Scientific Officer, who is an officer of the company, sold common stock on 12/15/2025. The transactions involved sales of 7,704 shares at a weighted average price of $29.9469 and 796 shares at a weighted average price of $30.6772, both coded as open-market sales.
These sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. Following the reported transactions, the officer directly beneficially owns 392,642 shares of Rapport Therapeutics common stock.
Rapport Therapeutics, Inc. (RAPP) reported insider stock sales by its Chief Executive Officer and director on a Form 4. On 11/17/2025, the reporting person sold 2,777, 3,056, 2,242 and 2,841 shares of common stock in multiple transactions at weighted average prices of $24.9246, $25.4303, $24.9107 and $25.437, respectively. The filing states these trades were made under Rule 10b5-1 trading plans adopted on December 12, 2024. Following the transactions, the reporting person directly owns 576,802 shares and has additional indirect holdings through the Dorothy Ceesay Irrevocable Trust and the Ceesay Family Irrevocable Trust, while disclaiming beneficial ownership of those trust shares except for any pecuniary interest.